Travere Therapeutics, Inc. lost $0.29 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a loss of $1.29 per diluted share. The table below carries 15 fiscal years, from 2012 to 2025, and the quarters Travere Therapeutics, Inc. has filed alongside them.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Travere Therapeutics, Inc. lost $0.29 per diluted share in fiscal year 2025.
Travere Therapeutics, Inc. (TVTX) reported a loss of $4.08 per diluted share in fiscal year 2024 and a loss of $0.29 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Travere Therapeutics, Inc. (TVTX) reported a loss of $1.29 per diluted share over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
Travere Therapeutics, Inc. (TVTX) reported -$0.55 in diluted earnings per share in Q3 2026. This represents a decrease of 296.4% from the same quarter a year earlier.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Travere Therapeutics, Inc. (TVTX) reported on that line in every period on record.